News und Analysen
EQS-Adhoc: Nagarro SE ended talks regarding a potential take-private to pursue alternative strategic option
EQS-Adhoc: Nagarro SE ended talks regarding a potential take-private to pursue alternative strategic option
EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
EQS-Adhoc: Nemetschek SE: Preliminary results for the financial year 2024 - Revenue growth exceeds outlook, profitability slightly above forecasted range
EQS-Adhoc: Nemetschek SE: Preliminary results for the financial year 2024 - Revenue growth exceeds outlook, profitability slightly above forecasted range
EQS-News: Nemetschek SE: Usman Shuja appointed to the Executive Board of the Nemetschek Group
EQS-News: Nemetschek SE: Usman Shuja appointed to the Executive Board of the Nemetschek Group
EQS-News: Change on the Management Board of 1&1 AG
EQS-News: Change on the Management Board of 1&1 AG
EQS-News: United Internet: Change in Management Board of United Internet AG
EQS-News: United Internet: Change in Management Board of United Internet AG
EQS-News: TeamViewer reports rapid customer adoption of its Al offering
EQS-News: TeamViewer reports rapid customer adoption of its Al offering
EQS-News: TeamViewer Q3 2025: TeamViewer continues to deliver ARR and revenue growth YoY with 46% Adj. EBITDA margin
EQS-News: TeamViewer Q3 2025: TeamViewer continues to deliver ARR and revenue growth YoY with 46% Adj. EBITDA margin
EQS-Adhoc: TeamViewer SE: TeamViewer discloses Q3 2025 results and updates FY 2025 pro forma guidance
EQS-Adhoc: TeamViewer SE: TeamViewer discloses Q3 2025 results and updates FY 2025 pro forma guidance
EQS-News: Q2 2025: TeamViewer delivers 15 % Enterprise Revenue growth yoy and strong Adj. EBITDA margin of 44 %; reiterates FY guidance
EQS-News: Q2 2025: TeamViewer delivers 15 % Enterprise Revenue growth yoy and strong Adj. EBITDA margin of 44 %; reiterates FY guidance
EQS-News: CVC successfully concludes public delisting offer for CompuGroup Medical
EQS-News: CVC successfully concludes public delisting offer for CompuGroup Medical
EQS-News: Delisting of CompuGroup Medical to become effective as of 24 June 2025
EQS-News: Delisting of CompuGroup Medical to become effective as of 24 June 2025
EQS-News: CompuGroup Medical issues joint reasoned statement recommending shareholders to accept CVC’s public delisting offer
EQS-News: CompuGroup Medical issues joint reasoned statement recommending shareholders to accept CVC’s public delisting offer
EQS-News: 2025 Annual General Meeting of TeamViewer SE – Shareholders elect new Supervisory Board member and approve all agenda items by a clear majority
EQS-News: 2025 Annual General Meeting of TeamViewer SE – Shareholders elect new Supervisory Board member and approve all agenda items by a clear majority
EQS-News: TeamViewer launches first Digital Workplace platform combining endpoint management, remote connectivity, AI, and DEX
EQS-News: TeamViewer launches first Digital Workplace platform combining endpoint management, remote connectivity, AI, and DEX
EQS-News: CompuGroup Medical and CVC plan delisting – public delisting offer announced by CVC
EQS-News: CompuGroup Medical and CVC plan delisting – public delisting offer announced by CVC
EQS-News: Q1 2025: TeamViewer Revenue up 7 % yoy, Enterprise ARR up 20 % yoy and Adj. EBITDA up 20 % yoy; FY guidance reiterated
EQS-News: Q1 2025: TeamViewer Revenue up 7 % yoy, Enterprise ARR up 20 % yoy and Adj. EBITDA up 20 % yoy; FY guidance reiterated
EQS-News: Q1/2025: CompuGroup Medical reports slow start into the year
EQS-News: Q1/2025: CompuGroup Medical reports slow start into the year
EQS-News: Final regulatory approval for voluntary public takeover offer – Strategic partnership between CVC and CompuGroup Medical takes effect upon completion of the offer
EQS-News: Final regulatory approval for voluntary public takeover offer – Strategic partnership between CVC and CompuGroup Medical takes effect upon completion of the offer
EQS-News: CGM reports FY 2024 financials in line with revised guidance and expects to return to growth path in 2025
EQS-News: CGM reports FY 2024 financials in line with revised guidance and expects to return to growth path in 2025
EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum
EQS-Adhoc: Ad-hoc: CompuGroup Medical SE & Co. KGaA intends to reduce the annual dividend for the financial year 2024 to the legal minimum
EQS-News: Final results of voluntary public takeover offer – CVC has secured 21.85% of total share capital and voting rights of CompuGroup Medical
EQS-News: Final results of voluntary public takeover offer – CVC has secured 21.85% of total share capital and voting rights of CompuGroup Medical
EQS-News: Strong FY 2024 performance: Revenue up by 9 % YoY and exceeded guidance range, Enterprise Revenue grows by 26 % YoY, and Adjusted EBITDA Margin reaches 44 %
EQS-News: Strong FY 2024 performance: Revenue up by 9 % YoY and exceeded guidance range, Enterprise Revenue grows by 26 % YoY, and Adjusted EBITDA Margin reaches 44 %
EQS-News: Successful conclusion of initial acceptance period of CVC offer for CompuGroup Medical – Additional acceptance period from 29 January to 11 February 2025
EQS-News: Successful conclusion of initial acceptance period of CVC offer for CompuGroup Medical – Additional acceptance period from 29 January to 11 February 2025